Posted on

Increasing PrEP Uptake in PWID

Take our post-test to claim CME credits.

To read a companion newsletter click here.

People who inject drugs (PWID) are at risk for HIV infection from both sexual- as well as injection-related causes. What can clinicians do to reduce the incidence of infection and improve their patients’ health? In this issue, Dr. Jessica Taylor from The Boston University School of Medicine and Boston Medical Center takes us into the clinic to explain how current evidence-based strategies can increase the uptake of HIV pre-exposure prophylaxis in this vulnerable population.

Podcast (ehiv): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

Posted on

Clinical Insight: Engaging PWID in HCV Care

Volume 6, Issue 4.

People who inject drugs (PWID) comprise a rapidly growing population of HCV-infected people who have historically been difficult to reach and treat. But without engagement in HCV care, PWID will continue to transmit the virus and impede efforts for hepatitis C eradication.

In this issue, Dr. Arthur Kim from Massachusetts General Hospital and Harvard Medical School provides a clinical perspective on identifying and overcoming the barriers that prevent PWID from effectively receiving HCV treatment.

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Podcast (eviralhepatitis): Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS